Welcome to our dedicated page for Jack Nathan Med news (Ticker: JNHMF), a resource for investors and traders seeking the latest updates and insights on Jack Nathan Med stock.
Jack Nathan Med (JNHMF) delivers innovative healthcare solutions through advanced medical devices and diagnostic technologies. This news hub provides investors and industry professionals with essential updates about the company's clinical advancements and market position.
Access timely announcements including earnings reports, product launches, regulatory milestones, and partnership developments. Our curated collection ensures you stay informed about JNHMF's contributions to medical imaging systems, therapeutic devices, and diagnostic equipment innovations.
Discover press releases detailing clinical-grade technology deployments and research breakthroughs. All content is verified for accuracy, providing reliable insights into the company's operational strategies and healthcare impact without speculative commentary.
Bookmark this page for streamlined access to JNHMF's evolving story in the medtech sector. Regularly updated with official communications, it serves as your primary resource for understanding the company's role in shaping modern clinical solutions.
Jack Nathan Medical Corp. announced the results of its annual and special shareholders' meeting held on June 27, 2024. All agenda items were approved, including the election of directors with voting percentages ranging between 86.9% and 89.6%. Additionally, MNP LLP was reappointed as the company's auditors, with an overwhelmingly favorable vote of 99.97%. A resolution to grant stock options under the Omnibus Equity Incentive Plan was also passed. Bharat Choudhary, the CFO, is resigning effective June 28, 2024, and the company is actively searching for his replacement.
Jack Nathan Health (TSXV: JNH, OTCQB: JNHMF) announced its Q1 fiscal 2025 financial results, highlighting a 25% revenue growth to $5.28 million, driven by its clinic operations and expansion to 243 locations globally. Despite the revenue increase, the company reported an operating loss of $1.61 million due to higher expenses associated with new clinic openings. The company now operates 82 clinics in Canada and 161 clinics in Mexico, predominantly within Walmart locations. As of April 30, 2024, JNH reported cash of $1.77 million, total assets of $8.90 million, and total liabilities of $16.77 million. The company has 87,099,159 common shares outstanding and a secured convertible debenture with Walmart worth $8 million, maturing in July 2026.
Jack Nathan Health reported a 24% growth in revenue for the fiscal year 2024, reaching $19.1 million. The company expanded to 245 locations globally, with a focus on Canada and Mexico. The partnership with Walmart drove robust financial outcomes, leading to an increase in revenue. The company opened 9 new clinics in Canada and experienced significant growth in Mexico. Operating expenses decreased, resulting in a smaller net loss compared to the previous year. The balance sheet showed an increase in cash and total assets, with total liabilities also increasing. The company had 87,099,159 common shares outstanding as of January 31, 2024.
FAQ
What is the current stock price of Jack Nathan Med (JNHMF)?
What is the market cap of Jack Nathan Med (JNHMF)?
